UNICEF signs supply agreement for Clover COVID-19 vaccine – Community News
Covid-19

UNICEF signs supply agreement for Clover COVID-19 vaccine

NEW YORK/COPENHAGEN, December 7, 2021 – UNICEF and Clover Biopharmaceuticals Ltd. signed a long-term agreement on behalf of the COVAX Facility for the supply of the Clover COVID-19 vaccine.

Through the supply agreement, UNICEF will have access to up to 414 million doses of Clover’s COVID-19 vaccine through the end of 2022. These doses were allocated to the COVAX facility through an Advance Purchase Agreement (APA) signed between Gavi, the Vaccine Alliance and Clover Biopharmaceuticals on June 30, 2021. The vaccine will be delivered to participating countries and territories in the Advance Market Commitment (AMC) of the COVAX Facility, as well as to self-financing participants.

This agreement further expands UNICEF’s supplier base of COVID-19 vaccines. UNICEF has already signed supply agreements with vaccine manufacturers, including the Serum Institute of India, Pfizer, AstraZeneca, Human Vaccine, Moderna, Janssen Pharmaceutica NV, Sinopharm and Sinovac. The addition of Clover’s vaccine to the portfolio further diversifies by providing access to the first protein subunit vaccine.

A condition for purchase by UNICEF under this agreement is that the product achieves a WHO Emergency Use Listing (EUL) to confirm the quality, safety and efficacy of the vaccine.

Deliveries could start as early as the first quarter of 2022, provided countries are ready to receive them and the WHO awards an EUL. The COVAX allocation framework will determine dose allocations to COVAX participants, taking into account vaccination coverage, the country’s capacity to store and administer doses, vaccine delivery to date via COVAX, operational and delivery aspects, and other parameters.

The goal of the COVAX facility is to address the acute phase of the global pandemic by providing rapid, fair and equitable access to safe and effective vaccines for all participating countries and territories, regardless of income level.

The COVAX facility, led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and WHO, along with UNICEF, aims to provide access to high-quality COVID-19 vaccines, helping to protect primary health care and social workers , as well as other high-risk and vulnerable groups.

# # # # # #

About the COVAX facility
COVAX is the vaccine pillar of the Access to COVID-19 Tools (ACT) Accelerator, a pioneering global collaboration to accelerate development, manufacturing and equitable access to COVID-19 tests, treatments and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO. The goal is to accelerate the development and production of COVID-19 vaccines and ensure fair and equitable access for every country in the world. UNICEF, in partnership with the PAHO Revolving Fund, is leading efforts to procure and deliver doses of COVID-19 vaccines on behalf of the COVAX facility.

Media contacts

Stephanie Brickman
UNICEF Copenhagen
Phone: +45 408 74876
Email: [email protected]

Tess Ingram
UNICEF New York
Phone: +1 347 593 2593
Email: [email protected]